🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mainz
Clinical trial register · Germany

Clinical Trials in Mainz, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals21 AstraZeneca19 Johannes Gutenberg University Mainz16 GlaxoSmithKline11 Sanofi11
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Mainz

336 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Study Comparing Two Administration Pathways for Adenosine During Microvascular Function Assessment
NCT06269874Microvascular Coronary Artery Disease
Johannes Gutenberg University Mainz
Not applicable
40
Mainz
2027-03-02
Not yet open
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
NCT07839819Advanced Solid Tumor
DrugsPM54·Doxorubicin·Irinotecan
PharmaMar
Phase 1/2
231
Buckow, Mainz
2026-11-12
Not yet open
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
NCT07474649Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
DrugsBempedoic acid·Ezetimibe·Rosuvastatin·Atorvastatin
Daiichi Sankyo
Phase 3
103
Berlin, Hamburg, Mainz, Mannheim
2026-09-30
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Mainz, Stuttgart
2026-09-29
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Bad Homburg, Bonn, Brandenburg, Gütersloh, Homburg, Kassel, Mainz, Mannheim
2026-09-29
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
DrugHizentra
CSL Behring
Phase 3
63
Giessen, Mainz
2026-09-15
Not yet open
XR2ESILIENCE - XR-Based Resilience Training for Stress and Mental Health in Healthcare Workers
NCT07544498Occupational Stress, Work-Related Stress, Mental Health, Burnout
Medical University of Graz
Not applicable
232
Mainz
2026-09
Not yet open
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
NCT07752121Myelodysplastic Neoplasms
DrugLuspatercept
Bristol-Myers Squibb
Observational
190
Mainz
2026-08-24
Not yet open
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979Gastric / Gastroesophageal Junction Adenocarcinoma
DrugsFolfox·Cadonilimab·Nivolumab
Akeso
Phase 3
900
Essen, Frankfurt, Mainz, Marburg
2026-08-20
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Frankfurt, Hamburg, Landsberg am Lech, Leipzig, Mainz, Rheine
2026-08-07
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
Mainz, Hamburg, Heidelberg, Leipzig, München, Würzburg
2026-07-27
Recruiting
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
DrugZugo-cel
CRISPR Therapeutics AG
Phase 1/2
60
Cologne, Hannover, Hanover, Mainz
2026-07-17
Not yet open
Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
NCT07653139Haemophilia A
Novo Nordisk A/S
Observational
150
Mainz
2026-07-10
Recruiting
Stroke Care During the COVID-19 Pandemic
NCT07795021Stroke (CVA) or TIA
Dr. Yaroslav Winter
Observational
40,000
Mainz
2026-07-01
Recruiting
Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
NCT07647471Pediatric Cancer Patients
Universität Duisburg-Essen
Not applicable
346
Berlin, Bonn, Cologne, Essen, Frankfurt, Hamburg, Jena, Mainz
2026-07-01
Not yet open
AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation
NCT07604727Atrial Fibrillation (AF), Heart Failure, Cardiac Pacing
University Medical Center Groningen
Not applicable
292
Gelsenkirchen, Mainz, München, Paderborn, Stade
2026-07
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
218
Aachen, Berlin, Freiburg im Breisgau, Halle, Mainz
2026-05-11
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals
Phase 2
99
Halle, Greifswald, Mainz
2026-05-06
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Bad Abbach, Hamburg, Mainz, München
2026-04-13
Recruiting
DEfeating PEnile CAncer-2
NCT07378670Penile Cancer, Penile Neoplasms Malignant
University Hospital Tuebingen
Not applicable
80
Berlin, Dresden, Erlangen, Mainz, Mannheim, München, Rostock, Tübingen
2026-04-10
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Munich, Hanover, Mainz
2026-03-26
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Berlin, Cologne, Hamburg, Hanover, Mainz, München
2026-03-23
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
DrugsVisugromab RDE·Visugromab·Opdivo·Lenvatinib
CatalYm GmbH
Phase 2
104
Hanover, Mainz, Frankfurt
2026-03-19
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
Cologne, Lübeck, Frankfurt, Mainz
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Berlin, Frankfurt, Hamburg, Heidelberg, Leipzig, Mainz, Mannheim, Ulm
2026-03-13
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Bad Bevensen, Bad Nauheim, Berlin, Dresden, Hamburg, Jena, Mainz
2026-03-03
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
DrugsDarzalex·AZD0120·Velcade·Carfilzomib
AstraZeneca
Phase 3
508
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz
2026-02-23
Active, closed
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Dresden, Mainz
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg
2026-02-16
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Aachen, Berlin, Bielefeld, Chemnitz, Mainz, Mannheim, Schwerin, Siegen
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Cologne, Dresden, Duisburg, Essen, Hamburg, Leipzig, Lingen, Mainz
2026-02-06
Recruiting
A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke
NCT07367100Ischemic Stroke
Neuravi Limited
Not applicable
74
Heidelberg, Kiel, Mainz, Solingen
2026-02-02
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263Hidradenitis Suppurativa
DrugZasocitinib
Takeda
Phase 2
90
Bad Bentheim, Bochum, Mainz, Berlin
2026-01-26
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Bad Bentheim, Berlin, Cottbus, Hamburg, Heidelberg, Mainz, Remscheid, Witten
2026-01-15
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
2026-01-09
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975Hidradenitis Suppurativa (HS)
Navigator Medicines, Inc.
Phase 2
150
Bochum, Frankfurt, Kiel, Lübeck, Mainz
2026-01-05
Recruiting
A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy
NCT07218523Bowel Cleansing Prior to Clinical Procedures
DrugsPicoprep·Plenvu
Norgine
Phase 3
212
Regensburg, Münster, Wuppertal, Mainz, Berlin
2025-12-29
Recruiting
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
NCT06975787Lupus Nephritis (LN)
DrugsVonsetamig·Odronextamab
Regeneron Pharmaceuticals
Phase 1
90
Regensburg, Mainz
2025-12-22
Recruiting
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
NCT07110038Penile Squamous Cell Carcinoma (PSCC)
DrugsAvelumab·Enfortumab Vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
25
Dresden, Düsseldorf, Mainz, Mannheim, Munich, Regensburg, Rostock, Tübingen
2025-12-16
Recruiting
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
NCT06722183Colorectal Cancer
DrugTislelizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
33
Amberg, Berlin, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Mainz, München
2025-12-16
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
110
Bad Bentheim, Cologne, Münster, Bonn, Mainz
2025-12-04
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Münster, Mainz, Berlin, Dresden, Erlangen
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Bonn, Jena, Mainz, München, Münster
2025-12-02
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Berlin, Darmstadt, Leipzig, Mainz
2025-11-27
Active, closed
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015Atopic Dermatitis
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
200
Augsburg, München, Bad Bentheim, Berlin, Dresden, Frankfurt, Friedrichshafen, Mainz
2025-11-24
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
250
Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster
2025-11-13
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Bonn, Sulzbach, Cologne, Giessen, Mainz, München, Münster, Tübingen
2025-11-10
Active, closed
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577Atopic Dermatitis
DrugGIA632
Novartis Pharmaceuticals
Phase 2
34
Berlin, Hamburg, Mainz
2025-11-10
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
DrugBrivekimig
Sanofi
Phase 2
208
Bochum, Bramsche, Frankfurt, Kiel, Mainz, Münster, Würzburg
2025-11-06
Recruiting
Comparing a Suture-based System for the Removal of Arterial and Veinous ECMO Cannulas to the Standard Approach
NCT07019662VA-ECMO
IHF GmbH - Institut für Herzinfarktforschung
Not applicable
102
Frankfurt, Mainz
2025-10-27
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Bendorf, Berlin, Essen, Frankfurt, Hamburg, Leipzig, Mainz, Offenbach
2025-10-22
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
1,196
Berlin, Frankfurt, Mainz, München
2025-10-20
Recruiting
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731Phenylketonuria
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
Mainz, Münster
2025-10-20
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
Kiel, Mainz
2025-10-08
Recruiting
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
120
Dresden, Halle, Mainz
2025-10-01
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
80
Aachen, Leipzig, Mainz, Tübingen
2025-09-29
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Freiburg im Breisgau, Langenau, Mahlow, Hamburg, Bad Bentheim, Münster, Mainz, Quedlinburg
2025-09-22
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
DrugDupilumab
Sanofi
Phase 4
218
Mainz
2025-09-22
Recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110Plaque Psoriasis
AbbVie
Observational
700
Friedrichshafen, Kulmbach, Munich, Potsdam, Dortmund, Mainz, Mölln, Hamburg
2025-09-09
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Ulm, Cologne, Mainz, Frankfurt
2025-08-26
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Paroxetine·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Berlin, Essen, Mainz, München, Tübingen
2025-08-12
Recruiting
HOPE Against Cancer Recurrence in HCC
NCT06717919Liver Transplantation, HCC, Oncological Outcomes
Philipp Dutkowski
Phase 4
220
Essen, Hamburg-Eppendorf, Hanover, Heidelberg, Mainz, München
2025-08-01
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
Düsseldorf, Mainz, Saarbrücken, Wuppertal
2025-07-24
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
Berlin, München, Bendorf, Lübeck, Darmstadt, Frankfurt am Main, Leipzig, Mainz
2025-07-24
Recruiting
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
NCT06940388Locally Advanced Rectal Cancer (LARC)
DrugTislelizumab
brenner baruch
Phase 2
134
Mainz
2025-07-23
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg
2025-07-21
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
DrugMezagitamab
Takeda
Phase 3
347
Aachen, Jena, Mainz
2025-07-15
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Mannheim, Münster, Mainz, Berlin, Aachen, Bremen, Hamburg, Munich
2025-07-14
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
DrugRuxolitinib
Incyte Corporation
Phase 3
159
Bad Bentheim, Bonn, Chemnitz, Dresden, Frankfurt, Göttingen, Kiel, Mainz
2025-06-17
Active, closed
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
NCT07029555Rheumatoid Arthritis
DrugPIT565
Novartis Pharmaceuticals
Phase 1
57
Jena, Mainz
2025-06-12
Recruiting
Prediction of Blood Pressure Outcomes Following Renal Denervation (PREDICT-RDN)
NCT06845579Uncontrolled Arterial Hypertension
Heart Center Leipzig - University Hospital
Not applicable
90
Mainz, Leipzig
2025-06-01
Not yet open
Role of the Blood-Brain Barrier in Stress Resilience: Investigating New Pathways Towards Pharmacological Augmentation of Stress Resilience
NCT06965868Stress Resilience, Blood-Brain Barrier Integrity, Mental Health
DrugMetformin
Leibniz-Institut für Resilienzforschung (LIR) gGmbH
Not applicable
122
Mainz
2025-06
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Berlin, Dresden, Frankfurt am Main, Hanover, Mainz, Tübingen
2025-05-28
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301Advanced Melanoma
DrugsEIK1001·Keytruda·Pembrolizumab
Eikon Therapeutics
Phase 2/3
740
Mannheim, Tübingen, Würzburg, Martinsried, Saxony, Buxtehude, Minden, Mainz
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Berlin, Essen, Frankfurt am Main, Hanover, Leipzig, Mainz, Munich, Nuremberg
2025-05-22
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Dresden, Berlin, Mainz, Tübingen
2025-05-22
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
Hamburg, Berlin, Hessen, Leipzig, Bendorf, Mainz
2025-05-21
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Frankfurt am Main, Mainz, Bad Bentheim, Dresden, Hamburg, Heidelberg, Magdeburg, Münster
2025-05-16
Recruiting
Effects of Autonomic Nervous System Modulation by Heart Rate Variability Biofeedback Training With Resonant Frequency Breathing on Glucose Metabolism in Individuals With Prediabetes
NCT06739993Prediabetes
Johannes Gutenberg University Mainz
Not applicable
60
Mainz
2025-05-14
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Berlin, Heidelberg, Mainz
2025-05-12
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Heidelberg, Villingen-Schwenningen, Frankfurt am Main, Mainz, Dresden, Leipzig, Berlin
2025-05-08
Recruiting
Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia
NCT06514495Agoraphobia; Panic, Social Anxiety Disorder
Johannes Gutenberg University Mainz
Not applicable
68
Mainz
2025-05-01
Recruiting
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
NCT06855329Progressive Pulmonary Fibrosis, Interstitial Lung Disease
University of Massachusetts, Worcester
Observational
500
Coswig, Mainz, Munich
2025-05-01
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Recruiting
Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years
NCT07460791Glaucoma
Johannes Gutenberg University Mainz
Observational
200
Mainz
2025-04-03
Recruiting
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
NCT06682962Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigment Dispersion Glaucoma
Okuvision GmbH
Not applicable
50
Mainz
2025-04-02
Recruiting
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
NCT06615102Cardiac Surgery, Vasoplegia
DrugsAngiotensin II·Noradrenalin
Universität Münster
Phase 3
1,022
Berlin, Bonn, Mainz, Münster
2025-03-31
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
Augsburg, Cologne, Hanover, Mainz
2025-03-10
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
DrugsMo-Rez·Dostarlimab·Bevacizumab
GlaxoSmithKline
Phase 1/2
305
Cologne, Leipzig, Mainz, München
2025-03-04
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Mainz, Berlin
2025-02-28
Active, closed
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793Relapsing Multiple Sclerosis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
28
Bochum, Essen, Mainz, Ulm
2025-02-24
Recruiting
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
NCT06456983Schizophrenia, Treatment Resistant Schizophrenia
Central Institute of Mental Health, Mannheim
Not applicable
140
Aachen, Augsburg, Göppingen, Göttingen, Hanover, Heidelberg, Ingolstadt, Mainz
2025-02-14
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973786Bipolar Depression
DrugsValproate acid·Lithium·Bupropion·Venlafaxine
Dr. Inge Winter
Phase 3
418
Bielefeld, Dortmund, Frankfurt am Main, Mainz, Münster
2025-02-11
Active, closed
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053Asthma
DrugGSK5784283
GlaxoSmithKline
Phase 2
307
Bendorf, Berlin, Darmstadt, Frankfurt, Fürstenwalde, Leipzig, Magdeburg, Mainz
2025-02-10
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Dresden, Hamburg, Leipzig, Mainz, Villingen-Schwenningen
2025-02-06
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
320
Berlin, Essen, Göttingen, Mainz
2025-02-03
Recruiting
Identification of Liver Fibrosis Biomarkers
NCT06819917Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Roche Diagnostics GmbH
Observational
575
Mainz
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Cologne, Homburg, Kiel, Mainz, München, Würzburg
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Frankfurt am Main, Bochum, Mainz, Dresden, Leipzig, Berlin
2025-01-29
Recruiting
Lumbar Drainage of Intraventricular Hemorrhage
NCT06510842Intraventricular Hemorrhage, Lumbar Drainage, External Ventricular Drainage
University Hospital Heidelberg
Not applicable
354
Heidelberg, München, Augsburg, Berlin, Düsseldorf, Frankfurt, Göttingen, Mainz
2025-01-16
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Heidelberg, München, Würzburg, Hamburg, Erfurt, Jena, Mainz, Bad Nauheim
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Chemnitz, Dresden, Mainz, München, Regensburg
2024-12-16
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Adrucil
Janssen Research & Development, LLC
Phase 3
700
Berlin, Frankfurt am Main, Heidelberg, Mainz, Munich
2024-12-12
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
724
Ahrensburg, Bendorf, Berlin, Delitzsch, Frankfurt, Leipzig, Magdeburg, Mainz
2024-12-12
Active, closed
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
NCT06675864Progressive Multiple Sclerosis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
28
Essen, Mainz, Ulm
2024-12-12
Recruiting
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
NCT06611319Hip Arthroplasty, Total, Prevention of Venous Thromboembolism
DrugRivaroxaban
Prof. Stavros Konstantinides, MD
Phase 3
2,932
Kremmen, Rüsselsheim am Main, Mainz, Dresden, Berlin
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Esslingen am Neckar, Heidelberg, Göttingen, Hanover, Mainz, Dresden, Halle, Großhansdorf
2024-11-25
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
DrugsBudesonide/Formoterol·Lunsekimig
Sanofi
Phase 2
556
Ahrensburg, Bendorf, Berlin, Frankfurt, Frankfurt am Main, Leipzig, Mainz
2024-11-07
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
DrugsRapcabtagene autoleucel·Rituximab
Novartis Pharmaceuticals
Phase 2
96
Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz
2024-10-29
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
DrugsIntismeran autogene·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
680
Heidelberg, Stuttgart, Kempten (Allgäu), Giessen, Oldenburg, Eschweiler, Münster, Mainz
2024-10-21
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Irinotecan
Janssen Research & Development, LLC
Phase 3
1,000
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Mainz
2024-10-18
Active, closed
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
NCT06335979Systemic Lupus Erythematosus, SLE
DrugPIT565
Novartis Pharmaceuticals
Phase 1
54
Berlin, Mainz
2024-10-08
Recruiting
Influence of Sarcopenia on the Course of the Diseases
NCT06829290Liver Cirrhosis, Cancer, Cachexia, Sarcopenia
Universitatsmedizin Mainz - 1. Medizinische Klinik
Observational
200
Mainz
2024-10-01
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
Augsburg, Bonn, Cottbus, Hanover, Mainz
2024-09-30
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Leipzig, Mainz
2024-09-30
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
DrugGSK4532990
GlaxoSmithKline
Phase 2
393
Bochum, Berlin, Kiel, Leipzig, Mainz
2024-09-27
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
DrugBelimumab
GlaxoSmithKline
Phase 3
440
Essen, Minden, Mainz, Würzburg
2024-09-11
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Mannheim, Bonn, Düsseldorf, Münster, Kiel, Mainz
2024-09-11
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Active, closed
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Tectonic Therapeutic
Phase 2
191
Mainz
2024-09-04
Recruiting
ATLAS (AltaValve) Pivotal Trial
NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation
4C Medical Technologies, Inc.
Not applicable
450
Berlin, Bonn, Cologne, Dortmund, Mainz, Oeynhausen, Trier, Ulm
2024-09-03
Recruiting
The TRICURE EU Pivotal Study
NCT06581471Tricuspid Valve Regurgitation, Heart Valve Disease, Cardiovascular Diseases
TRiCares
Not applicable
80
Mainz, Munich
2024-08-29
Active, closed
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772Coeliac Disease, Celiac Disease
DrugAmlitelimab
Sanofi
Phase 2
229
Berlin, Halle, Mainz
2024-08-29
Active, closed
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228Asthma
DrugsICS/LABA·Dupilumab
Regeneron Pharmaceuticals
Phase 4
120
Augsburg, Munich, Frankfurt am Main, Koblenz, Lübeck, Berlin, Leipzig, Mainz
2024-08-26
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Recruiting
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric LTD
Not applicable
15
Mainz, Leipzig, Berlin
2024-08-05
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Kirchheim unter Teck, Munich, Ludwigshafen, Berlin, Mainz
2024-08-05
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05958875Schizophrenia and Related Disorders, Early Treatment-Resistance
DrugClozapine
Dr. Inge Winter
Phase 4
418
Augsburg, Bielefeld, Dortmund, Frankfurt am Main, Mainz, Münster
2024-08-01
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
DrugsBomedemstat·Hydroxyurea
Merck Sharp & Dohme LLC
Phase 3
300
Landshut, Hanover, Aachen, Essen, Mainz, Halle, Jena, Berlin
2024-07-16
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
963
Langenau, Darmstadt, Löhne, Dülmen, Kiel, Berlin, Bramsche, Mainz
2024-07-11
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180Advanced Melanoma
DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Keytruda
Replimune, Inc.
Phase 3
400
Berlin, Dresden, Erfurt, Essen, Hamburg, Heidelberg, Kiel, Mainz
2024-07-11
Recruiting
Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson's Network
NCT06479083Parkinson Disease
Johannes Gutenberg University Mainz
Not applicable
1,354
Homburg, Mainz
2024-07-01
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Würzburg, Frankfurt am Main, Hanover, Aachen, Cologne, Mainz, Homburg, Berlin
2024-06-25
Recruiting
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
NCT07298343Celiac Disease
Dr. Falk Pharma GmbH
Phase 2
356
Mainz
2024-06-10
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682Atopic Dermatitis
DrugTralokinumab
LEO Pharma
Phase 3
195
Buxtehude, Dresden, Mainz, Osnabrück, Tübingen, Wuppertal
2024-06-10
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Herne, Lübeck, Mainz, Meerbusch
2024-06-06
Recruiting
Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure
NCT07016477Coronary Artery Disease, Aortic Valve Stenosis, Tomography, X-Ray Computed
Semmelweis University
Observational
1,000
Freiburg im Breisgau, Mainz, Tübingen
2024-06-01
Recruiting
Baroloop Multicenter Trial (Baroloop MCT)
NCT06518915Hypertension, Resistant to Conventional Therapy
neuroloop GmbH
Not applicable
120
Münster, Mainz, Dresden
2024-05-22
Active, closed
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT06321302Diabetic Retinopathy
Boehringer Ingelheim
Phase 2
190
Bonn, Mainz, Neubrandenburg, Tübingen, Ulm
2024-05-15
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Augsburg, Bad Bentheim, Hamburg, Kiel, Mainz, Münster, Witten
2024-05-08
Recruiting
Enhanced Valves Interventions and Safe AI Generated End Results
NCT07213531Heart Valve Disease, TAVI, M-TEER, TTVI
Montreal Heart Institute
Observational
21,000
Hamburg, Mainz
2024-05-01
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
Berlin, Cologne, Erfurt, Frankfurt, Göttingen, Immenhausen, Kiel, Mainz
2024-04-29
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugClazakizumab
CSL Behring
Phase 2/3
3,110
Berlin, Hessen, Kaiserslautern, Kiel, Leipzig, Mainz, Villingen-Schwenningen
2024-04-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Heidelberg, Heilbronn, Münster, Mainz, Dresden, Leipzig, Berlin
2024-04-10
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Munich, München, Rosenheim, Hanover, Frankfurt, Essen, Mainz, Leipzig
2024-04-03
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
579
Aachen, Berlin, Erlangen, Essen, Greifswald, Hanover, Mainz, München
2024-03-29
Recruiting
Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
NCT06268769Immunosuppression
DrugsTacrolimus Pill·Envarsus·Tacrolimus
Edward Geissler
Phase 4
300
Aachen, Berlin, Dresden, Hamburg, Hanover, Jena, Mainz, Münster
2024-03-09
Recruiting
Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer
NCT05180864Stomach Neoplasm
Amsterdam UMC
Not applicable
654
Mainz
2024-03-01
Recruiting
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
NCT06482684Mantle Cell Lymphoma
DrugsTecartus·Ibrutinib
Christian Schmidt, MD
Phase 2
150
Mainz, Munich
2024-02-15
Recruiting
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
NCT06279793Intensive Care Unit, Coronary Artery Bypass Grafting (CABG), High Risk Patients, Cardiopulmonary Bypass
GCP-Service International West GmbH
Phase 2
550
Augsburg, Berlin, Bonn, Göttingen, Hamburg, Kiel, Mainz, Münster
2024-02-15
Active, closed
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738Small Cell Lung Carcinoma (SCLC)
DrugsObrixtamig·Topotecan
Boehringer Ingelheim
Phase 1
69
Dresden, Erlangen, Heidelberg, Mainz, Würzburg
2024-02-14
Recruiting
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
NCT06207734Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
120
Berlin, Bremen, Dortmund, Friedrichshafen, Gerlingen, Gütersloh, Hamburg, Mainz
2024-01-17
Not yet open
Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.
NCT05312853Chronic Liver Disease
Johannes Gutenberg University Mainz
Observational
250
Mainz
2024-01-15
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
DrugsOdronextamab·Lenalidomide·Rituximab
Regeneron Pharmaceuticals
Phase 3
580
Mutlangen, Stuttgart, Munich, Frankfurt am Main, Essen, Mainz, Halle, Kiel
2023-12-28
Active, closed
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
NCT06087627Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
110
Adernach, Berlin, Chemnitz, Düren, Düsseldorf, Hamburg, Leipzig, Mainz
2023-12-27
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Erlangen, Munich, Blankenfelde-Mahlow, Bonn, Frankfurt am Main, Bad Bentheim, Münster, Mainz
2023-12-19
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
München, Nuremberg, Marburg, Hanover, Moers, Münster, Mainz, Großhansdorf
2023-12-15
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)
DrugsOdronextamab·Prednisone/Prednisolone·Cytoxan·Adriamycin
Regeneron Pharmaceuticals
Phase 3
904
Stuttgart, Mutlangen, Frankfurt am Main, Essen, Mainz, Homburg, Dresden, Berlin
2023-12-13
Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254Follicular Lymphoma (FL)
DrugsOdronextamab·Prednisone/Prednisolone·Cytoxan·Adriamycin
Regeneron Pharmaceuticals
Phase 3
822
Stuttgart, Würzburg, Mutlangen, Frankfurt am Main, Mainz, Dresden, Berlin, Kiel
2023-12-12
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Göttingen, Stade, Dresden, Berlin, Mainz, Münster, Tübingen
2023-12-07
Recruiting
Multi-professional Care Pathway and Network for the Promotion of Needs-oriented, Resident-oriented Exercise Therapy for Oncological Patients
NCT06185777Cancer, Exercise, Implementation
University Hospital Heidelberg
Not applicable
2,500
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Mainz, Dresden, Berlin
2023-12-01
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
1,650
Würzburg, Frankfurt am Main, Mainz, Homburg, Leipzig, Lübeck, Berlin
2023-12-01
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445NonSegmental Vitiligo
DrugPovorcitinib
Incyte Corporation
Phase 3
467
Erlangen, Frankfurt am Main, Friedrichshafen, Mainz, Memmingen
2023-11-29
Active, closed
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741Moderate to Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 2
396
Augsburg, Erlangen, Bad Bentheim, Mainz, Leipzig, Berlin, Darmstadt, Frankfurt
2023-11-15
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Darmstadt, Bielefeld, Bochum, Bonn, Mainz, Dresden, Leipzig, Magdeburg
2023-11-08
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Freiburg im Breisgau, Mainz, Minden, Münster, Tübingen
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Aachen, Bad Oeynhausen, Berlin, Dresden, Hanover, Mainz, München
2023-11-07
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Altenburg, Berlin, Dresden, Düsseldorf, Essen, Kiel, Lübeck, Mainz
2023-11-01
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Berlin, Dresden, Erlangen, Gauting, Großhansdorf, Mainz
2023-10-13
Active, closed
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa
NCT06095713Fabry Disease
DrugPegunigalsidase-alfa
Universität Münster
Observational
60
Berlin, Cologne, Hamburg, Hanover, Mainz, Müllheim, Münster, Würzburg
2023-10-01
Recruiting
Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition
NCT06125392Coronary Microvascular Disease, Coronary Vasospasm
Johannes Gutenberg University Mainz
Observational
1,000
Mainz
2023-09-30
Active, closed
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT05900141Hyperlipoproteinemia (a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
41
Frankfurt am Main, Berlin, Cloppenburg, Dresden, Erlangen, Mainz, München, Ulm
2023-09-29
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
DrugsTiragolumab·Avastin·Tecentriq·Atezolizumab
Hoffmann-La Roche
Phase 3
687
Esslingen am Neckar, Magdeburg, Mainz, Tübingen
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Minden, Mainz, Cologne, Düsseldorf, Tübingen
2023-09-13
Recruiting
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964Atopic Dermatitis
DrugTilrekimig
Pfizer
Phase 2
340
Bad Bentheim, Mainz, Magdeburg
2023-08-22
Recruiting
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
NCT05966493Persistent Corneal Epithelial Defect
Glaukos Corporation
Phase 2
84
Mainz, München
2023-08-17
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Leipzig, Aachen, Berlin, Cologne, Hanover, Mainz, Stuttgart, Villingen-Schwenningen
2023-08-08
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Cologne, Mainz, Dresden, Buch, Frankfurt am Main
2023-07-25
Active, closed
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
DrugsFutibatinib·Leucovorin·Irinotecan·Adrucil
Taiho Oncology, Inc.
Phase 2
53
Frankfurt, Mainz
2023-07-13
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443Moderate to Severe Asthma
DrugsICS/LABA·Povorcitinib
Incyte Corporation
Phase 2
247
Bendorf, Bonn, Frankfurt am Main, Hanover, Mainz
2023-07-11
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Augsburg, Hanover, Mainz, Trier, Magdeburg, Jena, Essen
2023-07-06
Recruiting
Effects of Flow Magnitude on Cardiorespiratory Stability During Nasal High Flow Therapy in Preterm Infants
NCT05908227Respiratory Distress Syndrome
Insel Gruppe AG, University Hospital Bern
Not applicable
150
Mainz
2023-07-01
Recruiting
Global Research Initiative for Patients Screening on MASH
NCT05651724MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
Julius Clinical
Observational
10,000
Mainz, Homburg
2023-06-30
Not yet open
Evaluation of PCD-CT Based Image Parameters in the Assessment and Quantification of Coronary Artery Disease
NCT05877768Coronary Artery Disease
University Medical Center Mainz
Observational
3,000
Mainz
2023-06-30
Active, closed
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480SLE
DrugEnvudeucitinib
Alumis Inc
Phase 2
408
Leipzig, Mainz, Munich
2023-06-26
Recruiting
Fit to Fight Childhood Cancer
NCT05867186Pediatric Oncology
Johannes Gutenberg University Mainz
Observational
100
Mainz
2023-06-20
Active, closed
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
NCT05755711Coronary Artery Disease
Shockwave Medical, Inc.
Observational
399
Mainz, Trier, Leipzig
2023-05-03
Active, closed
IMPACT EU Post-Market Clinical Follow-Up Study
NCT05756751Left Ventricular Dysfunction
Abiomed Inc.
Not applicable
123
Heidelberg, Aachen, Düsseldorf, Essen, Mainz, Halle, Kiel, Berlin
2023-04-27
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
288
Freiburg im Breisgau, Cologne, Leipzig, Herne, Mainz
2023-04-21
Active, closed
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931Endometrial Cancer
DrugSelinexor
Karyopharm Therapeutics Inc
Phase 3
257
Berlin, Hamburg, Kiel, Krefeld, Leipzig, Mainz, Mannheim, Munich
2023-04-18
Active, closed
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317Heart Failure
Edwards Lifesciences
Not applicable
100
Bad Oeynhausen, Cologne, Dresden, Heidelberg, Mainz
2023-04-01
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Esslingen am Neckar, Heidelberg, Erlangen, Giessen, Bielefeld, Bonn, Dortmund, Mainz
2023-03-15
Active, closed
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
NCT05798117Systemic Lupus Erythematosus, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
21
Freiburg im Breisgau, Mainz
2023-02-28
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
DrugBaricitinib
Eli Lilly and Company
Phase 3
595
Bad Bentheim, Berlin, Dresden, Frankfurt am Main, Hamburg, Mainz, München, Münster
2023-02-27
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
NCT05496998Mitral Regurgitation
Medtronic Cardiovascular
Not applicable
400
Bad Oeynhausen, Berlin, Bonn, Hamburg, Leipzig, Mainz, München, Ulm
2023-02-07
By invitation
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
NCT05718570Adult Growth Hormone Deficiency
DrugSomapacitan
Novo Nordisk A/S
Observational
400
Aachen, Frankfurt am Main, Halle, Mainz, München, Oldenburg, Würzburg
2023-02-03
Active, closed
Titanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis
NCT05367505Pelvic Fracture, Insufficiency Fractures, Mobility Limitation
University of Witten/Herdecke
Not applicable
50
Bad Kreuznach, Mainz, Wuppertal
2023-01-09
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
DrugsSunvozertinib·Pemetrexed·Carboplatin
Dizal Pharmaceuticals
Phase 3
324
Berlin, Gauting, Georgsmarienhütte, Heidelberg, Mainz, Oldenburg
2022-12-13
Active, closed
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316Advanced Melanoma
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 2
150
Essen, Hamburg, Heidelberg, Kiel, Mainz, München, Tübingen, Würzburg
2022-12-12
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant
Celcuity Inc
Phase 3
701
Bayreuth, Berlin, Dorf Mecklenburg, Lübeck, Mainz, Münster, Saarbrücken, Wuppertal
2022-12-08
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,060
Freiburg im Breisgau, Tübingen, Ulm, Mainz, Aachen, Braunschweig, Chemnitz, Hamburg
2022-11-10
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
822
Berlin, Erlangen, Essen, Frankfurt, Giessen, Hanover, Jena, Mainz
2022-11-08
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Berlin, Cologne, Hamburg, Heidelberg, Leipzig, Mainz, Würzburg
2022-10-13
Active, closed
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)
NCT05776459Hearing Loss, Sensorineural
DrugPrednisolone
AudioCure Pharma GmbH
Phase 2
210
Bensheim, Berlin, Dresden, Greifswald, Halle, Hamburg, Jena, Mainz
2022-10-13
Recruiting
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
NCT05452213Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female
DrugRibociclib
Institut fuer Frauengesundheit
Phase 4
1,000
Erlangen, Mainz, Bottrop, Amberg, Aschaffenburg, Augsburg, Bamberg, Berlin
2022-10-12
Active, closed
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
NCT05582902MDS, MDS/MPN
University of Leipzig
Observational
60
Berlin, Chemnitz, Dresden, Düsseldorf, Jena, Leipzig, Mainz, Mannheim
2022-10-11
Recruiting
INSIGHTFUL-FFR Clinical Trial
NCT05437900Coronary Artery Disease, Acute Coronary Syndrome
CoreAalst BV
Phase 4
2,500
Dresden, Fürth, Herford, Koblenz, Lahr, Mainz
2022-09-22
Active, closed
The Euro-CRAFT Registry
NCT05805462Coronary Microvascular Disease
CoreAalst BV
Observational
671
Mainz
2022-09-22
By invitation
Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment
NCT05825898Tricuspid Regurgitation
Ottawa Heart Institute Research Corporation
Observational
3,500
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Leipzig, Mainz
2022-09-01
Active, closed
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222NASH, Cirrhosis, Liver
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 3
845
Leipzig, Mainz, Berlin
2022-08-26
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
DrugsCeralasertib·Durvalumab
AstraZeneca
Phase 2
194
Berlin, Buxtehude, Heidelberg, Heilbronn, Kiel, Mainz, München, Regensburg
2022-08-11
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Munich, Ludwigshafen, Frankfurt am Main, Braunschweig, Cologne, Berlin, Mainz
2022-08-10
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus
Genentech, Inc.
Phase 3
373
Bottrop, Erlangen, Essen, Heidelberg, Mainz
2022-08-03
Recruiting
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT05417594Advanced Solid Malignancies
DrugsPalacaparib·Datopotamab deruxtecan·Trastuzumab deruxtecan·Temozolomide
AstraZeneca
Phase 1/2
695
Bayern, Berlin, Heidelberg, Mainz
2022-06-24
Active, closed
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837Phenylketonuria (PKU)
DrugPegvaliase
BioMarin Pharmaceutical
Phase 3
55
Berlin, Hamburg, Mainz
2022-06-17
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib
BioNTech SE
Phase 1
320
Cologne, Frankfurt, Hamburg, Mainz
2022-06-17
Recruiting
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678Phenylketonuria (PKU)
DrugPegvaliase
BioMarin Pharmaceutical
Observational
450
Cottbus, Hamburg, Leipzig, Mainz, Münster, Ulm
2022-06-06
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Aachen, Cologne, Dresden, Hamburg, Hanover, Lübeck, Mainz, Villingen-Schwenningen
2022-05-30
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548Fabry Disease
DrugsAgalsidase beta·Replagal·Venglustat·Migalastat HCl
Sanofi
Phase 3
104
Berlin, Hochheim am Main, Mainz, Würzburg
2022-05-03
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Bad Krozingen, Bonn, Dortmund, Leipzig, Mainz, München
2022-04-27
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Mainz, Dresden
2022-04-05
Active, closed
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790Polycythemia Vera
DrugRusfertide
Protagonist Therapeutics, Inc.
Phase 3
293
Aachen, Berlin, Dresden, Greifswald, Hamburg, Koblenz, Mainz
2022-04-01
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Würzburg, Mainz, Leipzig, Kiel, Berlin, Chemnitz, Essen, München
2022-03-25
Active, closed
Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
NCT05269862Parkinson Disease
Abbott Medical Devices
Not applicable
100
Tübingen, Düsseldorf, Mainz
2022-03-24
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Frankfurt am Main, Düsseldorf, Mainz, Dresden
2022-03-15
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
DrugVenglustat
Sanofi
Phase 3
122
Hochheim am Main, Mainz, München, Würzburg
2022-03-11
Active, closed
Fragility Fractures of the Pelvis (FFP)
NCT04182776Pelvic Fracture
AO Innovation Translation Center
Observational
420
Hamburg, Leipzig, Mainz
2022-03-01
Recruiting
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206Pruritus
DrugsFexofenadine·Dupilumab
Sanofi
Phase 3
284
Bad Bentheim, Berlin, Frankfurt, Mainz, Münster
2022-02-15
Active, closed
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
NCT04573023Mucopolysaccharidosis II
DrugsIdursulfase·JR-141
JCR Pharmaceuticals Co., Ltd.
Phase 3
86
Giessen, Hamburg, Höchheim, Mainz
2022-02-14
Recruiting
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043Multiple Myeloma, Plasma Cell Disorder
DrugHDP-101
Heidelberg Pharma AG
Phase 1/2
78
Berlin, Chemnitz, Cologne, Hamburg, Heidelberg, Kiel, Lübeck, Mainz
2022-02-07
Recruiting
Mainz Register of Patients With Sleep Disorders
NCT05321355Sleep Disorder, Sleep Disorder Parasomnia, Narcolepsy, Sleep Apnea
Johannes Gutenberg University Mainz
Observational
500
Mainz
2022-02-01
Recruiting
Respiratory Variation of Carotid Doppler Peak Velocity (CDPV) for Non-invasive Prediction of Fluid Responsiveness
NCT05185141Hemodynamic Instability
Johannes Gutenberg University Mainz
Observational
84
Mainz
2022-01-11
By invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases
DrugsKITE-197·SPRX002·KITE-753·Tecartus
Kite, A Gilead Company
Observational
1,500
Dresden, Hamburg, Heidelberg, Mainz, München, Würzburg
2021-12-15
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Cologne, Dresden, Mainz, München, Oldenburg
2021-10-28
Recruiting
tTF-NGR Randomized Study - STS
NCT05597917Soft Tissue Sarcoma
DrugTrabectedin
Universität Münster
Phase 3
126
Bad Saarow, Berlin, Dresden, Hanover, Heidelberg, Mainz, München, Münich
2021-10-26
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
2021-09-13
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Leipzig, Mainz, München
2021-08-19
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Wiesbaden, Mainz, Homburg, Chemnitz, Dresden, Leipzig, Lübeck, Berlin
2021-08-19
Active, closed
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
NCT04713514Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
DrugsTedopi·Keytruda·Pembrolizumab
ARCAGY/ GINECO GROUP
Phase 2
180
Dresden, Essen, Leipzig, Mainz, Mannheim, Ulm
2021-08-05
Active, closed
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370Pulmonary Embolism
Boston Scientific Corporation
Phase 4
544
Aachen, Bielefeld, Bonn, Chemnitz, Freiburg im Breisgau, Immenstädt, Lübeck, Mainz
2021-08-02
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
Cologne, Aachen, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Mainz
2021-07-28
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
NCT04862286Psoriasis
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
132
Bad Bentheim, Bonn, Münster, Mainz, Dresden, Kiel
2021-07-24
Active, closed
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Lupus Erythematosus, Systemic
DrugLitifilimab
Biogen
Phase 3
562
Göttingen, Hanover, Cologne, Münster, Mainz
2021-07-16
Recruiting
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
NCT04798261Pulmonary Embolism
Penumbra Inc.
Observational
1,500
Mannheim, Mainz, Weinheim
2021-06-25
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
1,054
Berlin, Hamburg, Herne, Magdeburg, Mainz, Ratingen
2021-06-17
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Mainz, Munich
2021-05-26
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
NCT04752774Spasticity
DrugsDysport·Corabotase
Ipsen
Phase 1/2
240
Bonn, Düsseldorf, Goettigen, Hamburg, Mainz, Munich, Troisdorf, Tübingen
2021-04-29
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
DrugsSorafenib·Tecentriq·Atezolizumab·Lenvatinib
Hoffmann-La Roche
Phase 3
557
Frankfurt, Hanover, Mainz, Tübingen, Ulm
2021-04-26
Active, closed
Observational Clinical Investigation of Arthrosamid in Knee Osteoarthritis
NCT05057559Knee Osteoarthritis
Contura
Observational
201
Leipzig, Mainz
2021-04-21
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
DrugsTafasitamab·Lenalidomide·Rituximab
Incyte Corporation
Phase 3
654
Amberg, Berlin, Essen, Giessen, Greifswald, Landshut, Mainz, Mannheim
2021-04-15
Recruiting
Tendyne European Experience Registry
NCT04898335Mitral Regurgitation
LMU Klinikum
Observational
400
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Leipzig, Mainz
2021-04-15
Active, closed
TRISCEND II Pivotal Trial
NCT04482062Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Edwards Lifesciences
Not applicable
864
Bad Oeynhausen, Bonn, Cologne, Dresden, Leipzig, Mainz, München
2021-04-09
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Ulm, Würzburg, Giessen, Münster, Koblenz, Mainz, Lübeck, Hamburg
2021-04-08
Recruiting
COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina
NCT04606459Coronary Microvascular Disease, Refractory Angina
Johannes Gutenberg University Mainz
Not applicable
144
Mainz
2021-04-01
Recruiting
ORIGIN® vs. VANGUARD® PS Observational Study
NCT04728542Arthroplasty, Replacement, Knee
Symbios Orthopedie SA
Observational
140
Mainz
2021-03-25
Recruiting
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT04772079Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
153
Münster, Mainz, Dresden, Berlin, Hamburg
2021-03-23
Recruiting
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04710576Chronic Graft-versus-host-disease
DrugAxatilimab
Syndax Pharmaceuticals
Phase 2
296
Dresden, Jena, Leipzig, Mainz, Münster, Regensburg
2021-03-04
Recruiting
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
NCT04545502Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection
Vascutek Ltd.
Observational
2,000
Berlin, Bonn, Freiburg im Breisgau, Hamburg, Leipzig, Mainz, Munich
2021-02-17
Active, closed
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
NCT04732871Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
1,720
Essen, Goch, Hamburg, Mainz, München, Wallerfing, Würzburg
2021-02-15
Recruiting
RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).
NCT04306458Esophageal Adenocarcinoma
University Medical Center Mainz
Not applicable
218
Mainz
2021-01-18
Active, closed
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04657991Melanoma
DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab
Pfizer
Phase 3
257
Tübingen, München, Bonn, Minden, Mainz, Dresden, Leipzig, Kiel
2021-01-15
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
DrugPembrolizumab
BioNTech SE
Phase 2/3
358
Berlin, Cologne, Hanover, Heidelberg, Iserlohn, Leipzig, Mainz, München
2021-01-07
Active, closed
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
NCT04597125Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer
Phase 4
654
Münster, Mainz
2020-11-09
Recruiting
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
NCT04688190Mitral Regurgitation, Mitral Valve Disease, Mitral Annular Calcification
Universitätsklinikum Hamburg-Eppendorf
Observational
1,000
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Lübeck, Mainz
2020-11-01
Recruiting
Abbott Vascular Medical Device Registry
NCT04573660Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
Abbott Medical Devices
Observational
3,784
Frankfurt am Main, Mainz, Leipzig, Bad Bevensen, Kiel
2020-10-25
Recruiting
MICRO: a Registry Study in Patients With Microvascular Angina
NCT04612322Microvascular Disease
Johannes Gutenberg University Mainz
Observational
1,000
Mainz
2020-10-10
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone
GlaxoSmithKline
Phase 3
302
Mainz, Tübingen, Würzburg
2020-10-01
Active, closed
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
NCT04526665Primary Biliary Cirrhosis
DrugElafibranor
Ipsen
Phase 3
161
Berlin, Frankfurt, Hanover, Kiel, Leipzig, Mainz
2020-09-24
Active, closed
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
NCT04503278Solid Tumor
BioNTech Cell & Gene Therapies GmbH
Phase 1
214
Berlin, Cologne, Erlangen, Hamburg, Hanover, Heidelberg, Mainz, Regensburg
2020-09-16
Active, closed
An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device (bRIGHT)
NCT04483089Tricuspid Valve Regurgitation
Abbott Medical Devices
Observational
511
Bonn, Mainz, Leipzig, Bad Berka, Bad Oeynhausen, Bad Rothenfelde, Berlin, Dortmund
2020-08-27
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
NCT04419649Myelodysplastic Syndromes, Cytopenia
DrugElritercept
Takeda
Phase 2
160
Bayreuth, Berlin, Bonn, Düsseldorf, Esslingen am Neckar, Halle, Leipzig, Mainz
2020-08-19
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
NCT04221477Lupus Nephritis
DrugsDiphenhydramine·Acetaminophen·Methylprednisolone·Obinutuzumab
Hoffmann-La Roche
Phase 3
271
Berlin, Dresden, Freiburg im Breisgau, Mainz, Tübingen
2020-08-10
Active, closed
MINIject Global Long-Term Follow-up Study
NCT04524416Open Angle Glaucoma, Ocular Hypertension
iSTAR Medical
Observational
116
Cologne, Mainz, München
2020-08-05
Active, closed
MitraClip REPAIR MR Study
NCT04198870Mitral Valve Regurgitation
Abbott Medical Devices
Not applicable
500
Ulm, Frankfurt am Main, Bad Oeynhausen, Mainz, München, Rostock
2020-07-21
Recruiting
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576Leukemia, Acute Lymphoblastic
DrugsInotuzumab Ozogamicin·Imatinib·Blinatumomab
Mats Heyman
Phase 3
6,430
Bielefeld, Bonn, Bremen, Hamburg, Krefeld, Mainz
2020-07-13
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Berlin, Lübeck, Bad Segeberg, Bonn, Frankfurt, Giessen, Mainz, Munich
2020-07-07
Active, closed
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
DrugTazemetostat
Epizyme, Inc.
Phase 3
599
Schwäbisch Hall, München, Mainz, Bonn, Mönchengladbach, Kiel, Berlin
2020-06-11
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337Medullary Thyroid Cancer
DrugsVandetanib·Selpercatinib·Cabozantinib
Loxo Oncology, Inc.
Phase 3
291
München, Würzburg, Hanover, Essen, Mainz, Magdeburg, Berlin, Hamburg
2020-02-11
Recruiting
Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System
NCT04190602Mitral Regurgitation, Mitral Valve Disease, Mitral Valve Insufficiency, Mitral Valve Prolapse
NeoChord
Observational
500
Bonn, Frankfurt, Mainz
2020-02-09
Active, closed
MitraClip EXPAND G4 Study
NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation
Abbott Medical Devices
Observational
1,164
Lübeck, Essen, Mainz, Dresden, Bad Krozingen, Bad Oeynhausen, Bernau, Cologne
2020-01-17
Active, closed
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
NCT04230759Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
DrugDurvalumab
Goethe University
Phase 2
180
Darmstadt, Dresden, Freiburg im Breisgau, Essen, Kiel, Leipzig, Magdeburg, Mainz
2020-01-07
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Tübingen, Düsseldorf, Münster, Mainz, Homburg, Hamburg
2019-11-26
Recruiting
Alloplastic Total Temporomandibular Joint (TMJ) Replacement Registry
NCT03991728Temporomandibular Joint Disorders
AO Innovation Translation Center
Observational
200
Hanover, Leipzig, Mainz, Munich
2019-10-15
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Erlangen, Essen, Hamburg, Heidelberg, Mainz
2019-10-03
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
DrugsTucatinib·Trastuzumab emtansine
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Mainz, Kiel, Koblenz, München, Offenbach/ Main
2019-10-02
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Heidelberg, Greifswald, Mainz, Homburg, Leipzig, Donaueschingen, Dresden, Hamburg
2019-09-23
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Heidelberg, Ludwigshafen, Mainz, Mannheim, Würzburg
2019-09-17
Active, closed
LITMUS Imaging Study
NCT05479721NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
University of Oxford
Observational
450
Mainz, Würzburg
2019-09-04
Active, closed
TRILUMINATE Pivotal Trial
NCT03904147Tricuspid Regurgitation
Abbott Medical Devices
Not applicable
572
München, Bonn, Mainz, Leipzig
2019-08-21
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz
2019-08-12
Active, closed
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
NCT04046445Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
DrugEzabenlimab
Amal Therapeutics
Phase 1
96
Mainz
2019-07-22
Active, closed
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219Renal Cell Carcinoma
DrugsYervoy·Cabozantinib·Opdivo·Ipilimumab
Exelixis
Phase 3
855
Heidelberg, Tübingen, Frankfurt am Main, Münster, Mainz, Jena, Dresden
2019-06-25
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
415
Heidelberg, Mainz, Berlin, Bochum, Buxtehude, Cologne, Dresden, Essen
2019-06-04
Recruiting
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
DrugsAnzu-cel·Opdivo·Nivolumab
Immatics US, Inc.
Phase 1/2
375
Heidelberg, Munich, Würzburg, Bonn, Mainz, Dresden, Berlin, Hamburg
2019-05-14
Active, closed
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT03731260Indolent Systemic Mastocytosis
DrugAvapritinib
Blueprint Medicines Corporation
Phase 2
251
Aachen, Berlin, Hamburg, Lübeck, Mainz, Mannheim, Munich
2019-04-16
Active, closed
Fracture-Related Outcome Study for Operatively Treated Tibia Shaft Fractures
NCT03598530Tibial Fracture, Fracture of the Tibia Type AO/OTA 42
AO Clinical Investigation and Publishing Documentation
Observational
1,000
Mainz, Munich, Münster
2019-04-04
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429NASH - Nonalcoholic Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Berlin, Frankfurt am Main, Homburg, Leipzig, Mainz, Würzburg
2019-03-28
Recruiting
Distribution of Lymph Node Metastases in Esophageal Carcinoma
NCT03222895Esophageal Neoplasms, Lymph Node Metastases
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Observational
5,000
Mainz
2019-03-01
Recruiting
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108Multiple Myeloma
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 1/2
387
Essen, Mainz, Würzburg
2019-01-23
Active, closed
Obinutuzumab in Marginal Zone Lymphoma
NCT03322865Marginal Zone Lymphoma
DrugObinutuzumab
Christian Buske
Phase 2
56
Bochum, Essen, Freiburg im Breisgau, Göttingen, Halle, Koblenz, Mainz, Mannheim
2018-11-23
Active, closed
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
NCT03235245Unresectable Stage III Melanoma, Stage IV Melanoma
DrugsBinimetinib·Encorafenib·Ipilimumab·Nivolumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
271
Heidelberg, Mainz, Würzburg
2018-10-30
By invitation
Prevalence of Advanced Fibrosis in Patients Living With HIV
NCT04066608Fatty Liver Disease
Johannes Gutenberg University Mainz
Observational
300
Mainz
2018-10-01
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
730
Berlin, Cologne, Freiburg im Breisgau, Gauting, Heidelberg, Mainz, Münster, Oldenburg
2018-09-27
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Berlin, Cologne, Essen, Mainz, München
2018-06-26
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Munich, München, Mainz, Dresden, Leipzig, Halle, Magdeburg, Berlin
2018-06-21
Recruiting
Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds ("MUC-FIRE" Trial)
NCT03469609Enterostomy
University of Leipzig
Not applicable
120
Tübingen, München, Frankfurt am Main, Hanover, Witten, Mainz, Dresden, Leipzig
2018-06-18
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Aachen, Cologne, Dresden, Halle, Leipzig, Lübeck, Mainz
2018-05-03
Active, closed
AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System
NCT03339115Mitral Regurgitation, Mitral Valve Disease
Cardiovalve Ltd.
Not applicable
30
Bonn, Cologne, Lübeck, Mainz, München
2018-04-23
Active, closed
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373Neuroblastoma
DrugsNaxitamab·Gm-Csf
Y-mAbs Therapeutics
Phase 2
122
Hamburg, Mainz, Regensburg
2018-04-03
Recruiting
Mucopolysaccharidosis VII Disease Monitoring Program
NCT03604835Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
Ultragenyx Pharmaceutical Inc
Observational
50
Mainz
2018-01-29
Recruiting
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
NCT03383978Glioblastoma
DrugEzabenlimab
Johann Wolfgang Goethe University Hospital
Phase 1
42
Heidelberg, Mannheim, Mainz, Frankfurt
2017-12-01
Active, closed
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
NCT03218488Psoriasis
DrugUstekinumab
Janssen-Cilag International NV
Observational
135
Langenau, Mainz
2017-10-25
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
Aachen, Cologne, Essen, Hanover, Heidelberg, Leipzig, Mainz, München
2017-10-11
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Bad Belzig, Bochum, Cologne, Dortmund, Freiburg im Breisgau, Hanover, Leipzig, Mainz
2017-09-12
Active, closed
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
NCT03252938Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
DrugsEfti·Avelumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1
83
Bad Saarow, Cologne, Essen, Frankfurt, Giessen, Hamburg, Herne, Mainz
2017-08-15
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
DrugsAbraxane·Tremelimumab·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,186
Berlin, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Immenhausen, Mainz
2017-06-01
Active, closed
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03043872Small Cell Lung Carcinoma Extensive Disease
DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin
AstraZeneca
Phase 3
987
Aachen, Berlin, Gauting, Gera, Hamburg, Heidelberg, Mainz, Regensburg
2017-03-27
Active, closed
Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence
NCT02757274Urinary Incontinence, Stress
European Association of Urology Research Foundation
Observational
1,054
Hamburg, Mainz, Münster
2017-02-22
Active, closed
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
NCT02843035Gaucher Disease Type 1, Gaucher Disease Type 3
DrugsImiglucerase·Venglustat
Genzyme, a Sanofi Company
Phase 2
12
Mainz
2017-01-04
Active, closed
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
NCT03333187Bone Marrow Fibrosis
DrugJakavi
Universitätsklinikum Hamburg-Eppendorf
Phase 2
87
Aachen, Berlin, Bonn, Düsseldorf, Halle, Hamburg, Jena, Mainz
2016-12-21
Active, closed
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
NCT02954094Hepatocellular Cancer
Target PharmaSolutions, Inc.
Observational
10,000
Aachen, Berlin, Düsseldorf, Frankfurt, Hanover, Leipzig, Magdeburg, Mainz
2016-12
Active, closed
A Study of the ReCor Medical Paradise System in Clinical Hypertension
NCT02649426Hypertension, Vascular Diseases
ReCor Medical, Inc.
Not applicable
282
Düsseldorf, Erlangen, Freiburg im Breisgau, Homburg, Leipzig, Lübeck, Mainz
2016-03
Active, closed
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661Myelodysplastic Syndromes
DrugImetelstat sodium
Geron Corporation
Phase 2/3
289
Freiburg im Breisgau, Dresden, Leipzig, Aschaffenburg, Bonn, Düsseldorf, Mainz
2016-01-12
Active, closed
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
NCT02577926Polycythemia Vera (PV), Essential Thrombocythemia (ET)
DrugsJakavi·Ruxolitinib
RWTH Aachen University
Phase 2
207
Mannheim, Ulm, Winnenden, Aschaffenburg, Müchen, Nuremberg, Hamburg, Mainz
2015-10
Recruiting
The European NAFLD Registry
NCT04442334NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
Newcastle University
Observational
10,000
Aachen, Berlin, Freiburg im Breisgau, Mainz, Würzburg
2015-05-01
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsJakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Dresden, Jena, Aachen, Hamburg, Magdeburg, Mainz, Ulm
2015-03-05
Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134Parkinson's Disease
Boston Scientific Corporation
Observational
1,500
Berlin, Cologne, Düsseldorf, Freiburg im Breisgau, Hamburg, Hamm, Kiel, Mainz
2014-03-04
Active, closed
Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS)
NCT02181049Childhood and Adolescence Cancer (Survivors and Deceased)
CVSS study
Observational
1,000
Mainz
2013-10
Recruiting
Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registry
NCT02180178Coronary Artery Disease, Microvascular Dysfunction
Johannes Gutenberg University Mainz
Observational
1,000
Mainz
2013-09
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Alexion Pharmaceuticals, Inc.
Observational
300
Munich, Essen, Mainz, Berlin
2013-05-30
Recruiting
VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE
NCT02156401Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
Johannes Gutenberg University Mainz
Observational
2,000
Mainz
2013-04
Active, closed
MyoVasc Study on the Development and Progression of Heart Failure
NCT04064450Heart Failure
Johannes Gutenberg University Mainz
Observational
3,289
Mainz
2013-01
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Berlin, Bochum, Bonn, Freiburg im Breisgau, Giessen, Halle, Hamburg, Mainz
2004-09-15
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Berlin, Düsseldorf, Giessen, Hamburg, Mainz, Oberhausen
1991-04-01
Rows per page Showing 1–336 of 336
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/mainz

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 336 of those studies with a site in Mainz.

How many clinical trials are recruiting in Mainz?

171 of the 336 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 13 have not yet opened recruitment, 145 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Mainz), 336 studies
PhaseStudiesRecruitingShare
Phase 31185135.1%
Phase 2653019.3%
Observational623618.5%
Not applicable382311.3%
Phase 1/220126%
Phase 11484.2%
Phase 41163.3%
Phase 2/3852.4%

Most active sponsors

Lead sponsors with the most studies (Mainz)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals216
AstraZeneca199
Johannes Gutenberg University Mainz1612
GlaxoSmithKline116
Sanofi113
Bristol-Myers Squibb98
Abbott Medical Devices82
Regeneron Pharmaceuticals86
Incyte Corporation73
Boehringer Ingelheim63
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.